PB 67 of 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 3) 2025

I, Rebecca Richardson, as delegate of the Minister for Health and Ageing, make the following Determination.

Dated 4 June 2025    

Rebecca Richardson

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing

Contents

1  Name

2  Commencement

3  Authority

4  Schedules

Schedule 1—Amendments—General

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

Schedule 2—Amendments commencing immediately after the commencement of Schedule 2 to the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

Schedule 3—Amendments—Additional designated brands effective from 1 November 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Name

 (1) This instrument is the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 3) 2025.

 (2) This instrument may also be cited as PB 67 of 2025.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 99ADHC(2) of the National Health Act 1953.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments—General

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (table)

Omit:

Schedule 2—Amendments commencing immediately after the commencement of Schedule 2 to the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (after table item dealing with the brand Estalis continuous 50/140 of the drug Estradiol with norethisterone in the form Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8)

Insert:

2  Section 5 (after table item dealing with the brand Rosuzet Composite Pack of the drug Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium))

Insert:

3  Section 5 (after table item dealing with the brand Rosuzet Composite Pack of the drug Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium))

Insert:

4  Section 5 (after table item dealing with the brand Rosuzet Composite Pack of the drug Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium))

Insert:

5  Section 5 (after table item dealing with the brand Micolette of the drug Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate in the form Enemas 3.125 g-450 mg-45 mg in 5 mL, 12)

Insert:

Schedule 3—Amendments—Additional designated brands effective from 1 November 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (after table item dealing with the brand CIPLA TENOFOVIR + EMTRICITABINE 300/200 of the drug Tenofovir with emtricitabine in the form Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg)

Insert: